Loading stock data…
Axsome Therapeutics (AXSM)
$241.00-0.53 (-0.22%)
Market ClosedLast close Jul 24
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Axsome Therapeutics, Inc. in the Healthcare sector is trading at $241.00 with a market capitalization of $12.9B. Wall Street consensus targets $282.51 (21 analysts), implying a +17.2% move over the next 12 months. The stock is currently near its 52-week high of $260.19, remaining 32.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +17.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $191.20M↓ | $196.00M↑ | $170.99M↑ | $150.04M↑ | $121.46M |
| Gross Profit | $176.48M↓ | $183.67M↑ | $159.08M↑ | $136.59M↑ | $111.67M |
| Operating Income | -$62.77M↓ | -$36.02M↓ | -$32.92M↑ | -$44.82M↑ | -$55.47M |
| Net Income | -$64.54M↓ | -$28.56M↑ | -$47.23M↑ | -$47.97M↑ | -$59.41M |
Peer Comparison
JNJUNHPFE
Fundamentals
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextrometho...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.92B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-344.96%
Volume
Today's trading volume
411,997
Recent News
Axsome Therapeutics (AXSM) Stock is Attractive on the Back of its Key Drug
ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “Small Cap Growth Strategy”. A copy of the letter can be downloaded here. The Russell 2000 Growth Index increased by 25.6% in the second quarter, marking its third-best quarterly performance in two decades. The rally was fueled by enthusiasm for AI, strength […]
Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls
Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls
Jazz Pharmaceuticals (JAZZ) Refocuses Its Sleep Franchise, Is The Stock Still Cheap?
Jazz Pharmaceuticals (JAZZ) is back in focus after Axsome Therapeutics disclosed an FDA filing for AXS-12 in narcolepsy, highlighting Sunosi’s move from Jazz’s portfolio and refocusing attention on Jazz’s broader sleep-disorder franchise. See our latest analysis for Jazz Pharmaceuticals. Investors have responded to Jazz Pharmaceuticals’ sleep and oncology pipeline story with a 9.1% 1 month share price return and a 42.3% 5 year total shareholder return, while the 1 year total shareholder...
Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance
AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcolepsy and sets a May 2027 decision date.
3 Under-the-Radar Stocks to Buy and Hold
Sometimes, little-known stocks are worth buying.